Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Flibanserin
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The baseline means Female Sexual Function Index (FSFI) score was 13.3, with FSFI- desire score of 1.96 after 8 weeks on Addyi (flibanserin), an FDA-approved non-hormonal pill mean FSFI total score increased to 19.4, and the mean FSFI-d score increased to...
Brand Name : Addyi
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 15, 2022
Lead Product(s) : Flibanserin
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?